May 22nd 2025
Newly presented findings from the NEURO-TTRansform study identified thresholds for meaningful improvement in symptoms and disability, which were exceeded by eplontersen treatment.
Get direct access to interviews with experts, straight from the conference floor in Vienna, as well as the latest data and clinical news updates.
Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders
View More
BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease
View More
BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis
View More
Clinical Consultations™: Navigating the Evolving Treatment Landscape in Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of Subcutaneous Infusion as an Alternate Administration Route for Medical Interventions
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
ANX005 Outperforms IVIg and Plasma Exchange in Improving Guillain-Barré Syndrome Outcomes
Matched analysis from the IGOS dataset showed ANX005-treated patients had greater improvements in GBS disability scores over time compared with those receiving IVIg or plasma exchange.
Riliprubart Demonstrates Maintained Efficacy, Safety in Subgroup Analyses of CIDP
Subgroup data from a phase 2 CIDP trial showed riliprubart maintained consistent efficacy and safety across patient demographics, disease characteristics, and prior treatment exposures.
Eplontersen Slows Disability Progression and Deterioration of Gait Speed in ATTRv Polyneuropathy
Eplontersen showed promise in halting disability progression and improving gait speed in patients with hereditary amyloid polyneuropathy, according to recent study findings.
UK Analysis Shows Low Transthyretin Levels Linked to Increased Risk of Multiple Diseases
May 19th 2025A recently presented biobank data analysis showed associations between reduced transthyretin and higher incidence of conditions such as Alzheimer disease, cardiovascular disease, and rheumatoid arthritis.
Investigational Imlifidase Shows Rapid and Sustained Improvement of Guillain-Barré Syndrome Symptoms
Among patients with severe Guillain-Barré syndrome, imlifidase plus IVIg resulted in improved mobility, strength, and disability scores, with sustained benefit over a 6-month time period.
CIDP Agent Riliprubart Reduces Neurofilament Light in Phase 2 Subanalysis
New data from a phase 2 study presented at the 2025 PNS Annual Meeting showed that riliprubart reduced plasma NfL levels in CIDP, with greater reductions linked to stronger functional improvements.
FDA Clears Lumipulse Plasma Ratio as First Blood Test for Diagnosing Alzheimer Disease
The FDA approved Fujirebio's Lumipulse G p-tau217/β-Amyloid 1-42 Plasma Ratio as the first in vivo blood test for early Alzheimer’s detection, demonstrating high diagnostic accuracy with strong correlations to amyloid PET and CSF test results.
Plasma GFAP May Enrich Patient Selection, Reduce PET Scans Required for Alzheimer Trials
Targeting tau pathology in preclinical Alzheimer disease could benefit from recruiting individuals positive for both Aß and GFAP biomarkers, improving patient selection and cost effectiveness.
Frontotemporal Dementia Insights From Baptist Health’s Brain and Spine Symposium
Peter Gliebus, MD, discusses the clinical complexity of frontotemporal dementia and how Baptist Health’s symposium is helping to prepare the field for future advances in diagnosis and treatment.